Key result
Trastuzumab use in women with HER2-positive breast cancer was associated with a 16.21% incidence of cardiotoxicity, with risk factors including hypertension, obesity, and prior coronary artery disease.
Why the study?
What are the risk factors for developing cardiotoxicity in women receiving trastuzumab for HER2-positive breast cancer?
Observational (n=111)
No
What are the risk factors for developing cardiotoxicity in women receiving trastuzumab for HER2-positive breast cancer?
Postmenopausal status, hypertension, obesity, prior coronary artery disease, and smoking significantly increase the risk of trastuzumab-induced cardiotoxicity in women with HER2-positive breast cancer.
Answers are grounded in this paper and cite their sources.
May support enhanced cardiac surveillance in trastuzumab recipients with hypertension, obesity, or CAD; leaves open need for prospective validation.
BACKGROUND: Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated associated cardiotoxicity on clinical outcomes using trastuzumab in women referred to our clinic. MATERIALS AND METHODS: The study was made up of 111 women with human epidermal growth factor receptor 2-overexpressing breast cancer who received trastuzumab in the Medical Oncology Department, between 2010 and 2013. RESULTS: A > 10% reduction of the baseline fraction of the left ventricular ejection fraction was observed in 18 (16.21%) women. Two individuals (1.8%) suffered from symptomatic heart failure, seven women showed cardiac symptoms and nine women showed asymptomatic decline of left ventricular ejection fraction. Risk factors for cardiotoxicity in the group included: postmenopausal status (p = 0.01), hypertension (p = 0.002), obesity (p = 0.0001), previously diagnosed coronary artery disease (p = 0.0001) and smoking (p = 0.03). CONCLUSION: The aforementioned factors pose a risk for cardiotoxicity. We found postmenopausal status, hypertension, obesity, previous coronary artery disease and smoking to be associated with an increased risk of cardiac dysfunction in women using trastuzumab. While administering trastuzumab to women who have these conditions, one must be aware of the risk of cardiotoxicity of trastuzumab.
No takes yet. Share an insight, caveat, or question.
Günaldı et al. (2015) conducted an observational in Human epidermal growth factor receptor 2-overexpressing breast cancer (n=111). Trastuzumab was evaluated on > 10% reduction of the baseline fraction of the left ventricular ejection fraction. Trastuzumab use in women with HER2-positive breast cancer was associated with a 16.21% incidence of cardiotoxicity, with risk factors including hypertension, obesity, and prior coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: